Can brachytherapy be properly considered in the clinical practice? Trilogy project: The vision of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) Interventional Radiotherapy study group

Luca Tagliaferri, MD, PhD, Andrea Vavassori, MD, Valentina Lancellotta, MD, Vitelliana De Sanctis, MD, Fernando Barbera, MD, Vincenzo Fusco, MD, Cristiana Vidal, MD, Bruno Fionda, MD, Giuseppe Colloca, MD, Maria Antonietta Gambacorta, MD, PhD, Cynthia Aristei, MD, Renzo Corvò, MD, Stefano Maria Magrini, MD

1U.O.C. di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica e Ematologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy, 2Department of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy, 3Department of Radiation Oncology, Sant’Andrea Hospital “Sapienza” University, Rome, Italy, 4Radiation Oncology Department, Special Civil Hospital and Brescia University, Brescia, Italy, 5Department of Radiation Oncology, Centro di Riferimento Oncologico Regionale, Rionero in Vulture, Potenza, Italy, 6Radiation Oncology, Azienda Sanitaria Universitaria Integrata di Trieste (ASUITS), Trieste, Italy, 7Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy, 8Radiation Oncology Section, Department of Surgery and Biomedical Science, University of Perugia and Perugia General Hospital, Perugia, Italy, 9Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino and University of Genoa (DISSAL), Genoa, Italy

Abstract

Purpose: Brachytherapy (BT, interventional radiotherapy – IRT) is a kind of radiation therapy, in which the radioactive source is placed nearby or even inside the cancer itself. Even though this kind of radiation therapy appears effective and valuable, BT has been facing a slow but progressive decline over the past decades in Europe, particularly in Italy. Aims of this study were to identify the practical and theoretical reasons why BT is facing a slow decline in Italy, and to define a vision of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) and a strategy about this emerged issues.

Material and methods: A programmatic path divided into three steps like a trilogy was launched by AIRO Interventional Radiotherapy study group. The study group performed an initial data collection to highlight both the clinical and the educational topics and problems through specific surveys. After having analyzed the results of the surveys and shared a vision about the emerged issues, a specific strategy was adopted.

Results: Four relevant domains were identified and for each ones, a strategy has been discussed and defined. This manuscript shows in detail the individual actions defined (accomplished or in progress).

Conclusions: The AIRO vision implies that specific strategic interventions must be carried out in the field of national guidelines, education, research, and communication with patients and colleagues of other specialties in an interdisciplinary setting.

Key words: interventional radiotherapy, brachytherapy.
areas, or in specific patients who may benefit from the method in a balance between risks and benefits, such as elderly or frail patients [3,4].

Even though this kind of radiation therapy appears effective and valuable, BT has been facing a slow but progressive decline over the past decades in Italy and Europe. However, as experts in the field have highlighted, there are many signs of a renewed interest in BT thanks to new technologies. Even though no European data are available to indicate how much the number of centers offering brachytherapy has fallen, we may have an idea looking at the US National Cancer Database, which showed a decline in the proportion of patients treated with brachytherapy from 62.9% in 2004 to 51.3% in 2012 [5].

The actions supporting BT of the Italian Association Radiotherapy and Clinical Oncology (AIRO) study group on Interventional Radiography are included in the Trilogy project workflow.

To identify the practical and theoretical reasons why BT has faced a slow decline in Italy, a programmatic path divided into three steps like a trilogy was launched. The workflow of our approach is presented in Figure 1.

**Steps 1: Survey on clinical “state of the art” in Italy**

The Interventional Radiotherapy (Brachytherapy and Intraoperative Radiotherapy) study group of the AIRO conducted a clinical survey among all the Italian centers in order to analyze the use of BT in clinical practice.

In this first paper, a total of 66 questionnaires were obtained (33.5% of all brachytherapy centers in Italy), out of which 48 (74%) from non-academic hospitals, 6 (10%) from academic hospitals, and 12 (16%) from private institutions. Most centers (84%) had only one brachytherapy machine, and 44% did not deliver brachytherapy treatments or delivered less than demanded due to the reasons listed in Figure 2 [6].

**Steps 2: Survey on educational “state of the art” in Italy**

Then, the study group in collaboration with the Gemelli INTERVentional Radiotherapy ACTive Teaching School (Gemelli – INTERACTS – Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Università Cattolica del Sacro Cuore), implemented a specific survey aimed at all radiation oncology school directors in Italy to define the main educational training priorities related to BT.

In this second paper, a total of 23 school directors answered the survey. The results evidenced a wide heterogeneity in the learning activities available to trainees in BT across the country. While theoretical knowledge is adequately and homogeneously transmitted to trainees, the types of practice to which they are exposed varies significantly among different schools as reported in Table 1 [7]. Analyzing the different kinds of BT procedures/sites treated, three major groups can be identified according to the survey results:
1. Available and important for residential training (gynecologic, skin, anus, breast, esophagus, eye).
2. Important, but not sufficiently available (prostate, sarcoma, head and neck).
3. Apparently less relevant for residential training (lung, BT in children, and rectal).

**Step 3: Discussion and strategy identification**

The third step implied the discussion of the results obtained by the two surveys within the study group, with the definition of a possible strategy to overcome the identified problems. The “Task Force” for the in-depth discussion was composed of 12 people: chair (LT), elected chair (AV), past chair (CA), deputy chairs (CV, VDS), secretary (VL), and board members (FB, VF) of the AIRO Interventional Radiotherapy study group; a member of GIOGER (Italian Group of Geriatric Oncology) (GC), the chair of the scientific commission of the AIRO (RC), the AIRO president (SMM), and member of AIRO committee (MAG).

**AIRO Interventional Radiotherapy study group “state of the art” analysis**

There is a considerable amount of literature covering the topic of the role of BT in clinical practice; BT can be
indicated in exclusive, adjuvant, perioperative setting, but also to deliver a boost. In particular, there is evidence, which has proven that in selected cancers, such as cervical and prostate cancer, BT boost vs. no boost increases overall survival after external beam radiation therapy [8,9,10]. Moreover, there is evidence that the use of intensity modulated or stereotactic radiation therapy as alternatives to BT boost resulted in worse results not only in terms of overall survival, but also with regards to aesthetic results, and function and organ preservation [11,12,13,14]. It is worth to mention that BT plays an important role in treating elderly patients, particularly unfit, frail, or sarcopenic, in which a conservative therapeutic approach may be the best choice [15].

Analyzing the international scenario in terms of cultural background, it becomes clear that there is an adequate attention and consideration towards BT, supported by the presence of dedicated guidelines, with regard to several anatomical sites issued by the main European [16,17,18,19,20,21,22,23,24,25] and American societies [26,27,28]. For this reason, it is sensible to correlate the cultural diffusion of the role and importance of BT at a national level, with its actual diffusion in the clinical practice [29,30,31,32,33,34,35,36,37,38]. In our view, scientific national associations are called to a difficult, but at the same time, fundamental role in supporting and fostering the process of re-discovery of BT through a proper and dedicated vision.

**Vision of AIRO Interventional Radiotherapy study group**

After having analyzed and discussed the results of the AIRO Interventional Radiotherapy study group surveys, we shared a vision about the emerged issues, so the following strategy was adopted.

Four relevant domains were identified (Table 2):

1. Clinical practice.
2. Education.
3. Research.
4. Communication.

**Clinical practice**

First of all, the working group has fostered the inclusion of BT as a treatment option when clinically indicated, in the frame of national guidelines such as other study groups [39]. To facilitate such goal, representatives of the Interventional Radiotherapy study group were included both in the committee for the discussion of national guidelines and in other AIRO study groups (especially the ones dealing with gynecology, breast, and prostate cancer). Moreover, the members of the study group have been included in the AGENAS (National Agency for Regional Sanitary Services) working group for National Protocols (PDTA, Pathway Diagnostic Therapeutic Assisential).

In the near future, it will be fundamental to include BT within the interdisciplinary guidelines, taking into particular consideration not only cancer patients, but patients who could benefit from these treatments such as frail elderly [40]. For this reason, it has become important to develop synergies with other scientific societies such as GIOGER, SIGG (Italian Society of Geriatrics and Gerontology), and SIOG (International Society of Geriatric Oncology).

A series of systematic reviews and scientific papers were written under the auspices of the AIRO study group.

---

**Table 1.** Brachytherapy (BT) procedures in radiotherapy school. Modified from reference [7]

| BT procedures | Responders: available in the academic hospital or in the network (% of responders to the question) [% of the total participants to the survey] | Responders: should be part of resident’s training (% of responders to the question) [% of the total participants to the survey] | Total number of responders |
|---------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Gynecologic   | 21 (95%) [91%]                                                                                                                 | 13 (59%) [57%]                                                                                                                 | 22                       |
| Prostate HDR  | 4 (25%) [17%]                                                                                                                  | 15 (94%) [65%]                                                                                                                 | 16                       |
| Prostate LDR  | 6 (35%) [26%]                                                                                                                  | 13 (77%) [57%]                                                                                                                 | 17                       |
| Skin          | 14 (82%) [61%]                                                                                                                  | 9 (53%) [39%]                                                                                                                  | 17                       |
| Breast        | 8 (62%) [35%]                                                                                                                  | 8 (62%) [35%]                                                                                                                  | 13                       |
| Esophagus     | 9 (69%) [39%]                                                                                                                  | 8 (62%) [35%]                                                                                                                  | 13                       |
| Head and neck | 8 (57%) [35%]                                                                                                                  | 9 (64%) [39%]                                                                                                                  | 14                       |
| Lung (endobronchial) | 8 (80%) [35%]                                                              | 5 (50%) [22%]                                                                                                                  | 10                       |
| Sarcoma       | 9 (53%) [39%]                                                                                                                  | 12 (71%) [52%]                                                                                                                 | 17                       |
| Eye           | 9 (60%) [39%]                                                                                                                  | 8 (53%) [35%]                                                                                                                  | 15                       |
| Rectal        | 7 (54%) [30%]                                                                                                                  | 7 (54%) [30%]                                                                                                                  | 13                       |
| Anus          | 12 (75%) [52%]                                                                                                                 | 10 (63%) [43%]                                                                                                                 | 16                       |
| BT in children| 6 (60%) [26%]                                                                                                                  | 5 (50%) [22%]                                                                                                                  | 10                       |
and, at the moment, some of them have already been published, whereas others have been submitted [41].

A very interesting point, when considering the potential indications of BT across the different American and European guidelines, is to focus on the level of evidence available. In fact, for a large number of sites (including prostate, cervix, endometrium, breast, uvea, esophagus), the indications that can be found in the guidelines are actually based on randomized controlled trials (Table 3) [42].

Education

Another key point that emerged from our surveys is the need for an improvement of interventional radiotherapy education in Italy, especially to better define and harmonize programs at national level, particularly in practical teaching. For this reason, AIRO supported attendance in experienced centers or national and international courses on specific aspects of BT in order to facilitate the achievement of a satisfying level of BT knowledge among radiation oncologists. Moreover, AIRO endorsed University post-specialty courses (‘second level’ Masters) to allow professionals (already certified in radiation oncology) to acquire more complex BT knowledge. This will facilitate the recruitment of skilled professionals for hospitals’ BT units [43,44].

Research

The role of research in the field of interventional radiotherapy faces the same problems, highlighted in the clinical and educational settings. In fact, one of the greatest issues is the paucity of data due to the relatively small number of patients included in randomized clinical trials. As a possible solution to this problem, there has been a huge effort in creating a national and international network for dedicated research and big data sharing. The study group has thus supported the COBRA (COnsortium for BRachytherapy data Analysis) project born in the framework of the GEC-ESTRO for a wide national research database [45,46,47,48].

Communication

Finally, we believe that difficulties of communication with other specialists, with patients, and also institutional representatives regarding the present modality of the procedures, may represent a further obstacle. Active support to a more accurate knowledge of BT among colleagues and patients should be pursued. However, the ability to address the first three aspects (clinical practice, education, and research) may facilitate a better and more effective communication, especially with the specialists from other oncology branches. A task force was created

Table 2. Domains, issues, and relative solutions (accomplished or in progress) proposed according to the defined strategy

| Domain                | Issues                                                                 | AIRO defined strategy                                                                 |
|-----------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Clinical practice     | Inadequate evidence about the role of BT in national clinical guidelines | Inclusion of representatives of IRT study group within the committees for the discussion of national guidelines  |
|                       |                                                                        | Inclusion of IRT study group members in the AGENAS working group for national PDTA    |
|                       |                                                                        | Series of systematic reviews and scientific papers                                    |
|                       |                                                                        | Promoting synergies with other scientific societies                                   |
| Education             | Need for an adequate training (especially in residency programs)       | Consensus conference promotion                                                        |
|                       |                                                                        | Training meeting promotion                                                            |
|                       |                                                                        | University Master promotion                                                           |
| Research              | Difficulties in creating a network to gather strong evidence           | Support to the COBRA project born in the framework of the GEC-ESTRO for a wide international research database |
| Communication         | Difficulties in communication with other specialists, patients, and also institutional representatives | Development of specific printed or web-based booklets for patients                    |
|                       |                                                                        | The term “interventional radiotherapy” was introduced in the name of the study group and in routine clinical practice |

Table 3. Type of study supporting brachytherapy

| Site             | Type of study                  |
|------------------|--------------------------------|
| Cervix           | Randomized controlled trials   |
| Endometrium      | Randomized controlled trials   |
| Vulvo-vaginal    | Retrospective cohort studies   |
| Breast           | Randomized controlled trials   |
| Prostate         | Randomized controlled trials   |
| Head and Neck    | Retrospective cohort studies   |
| Uvea             | Randomized controlled trials   |
| Skin             | Retrospective cohort studies   |
| Esophagus        | Randomized controlled trials   |
| Anus             | Retrospective cohort studies   |
| Rectum           | Retrospective cohort studies   |
| Trachea          | Randomized controlled trials   |
| Soft tissue sarcoma | Randomized controlled trials   |
within the study group for the development of patient specific booklets both paper- and web-based. The term “interventional radiotherapy” was introduced in the name of the study group.

Changing the name allows several advantages, leading to better communication with colleagues and patients because it better explains the effective operational aspects of the technique. According to our view, it results also in better communication with the national institutional representatives, with a consequent smoother procedural and organizational crosstalk, resulting also in a more adequate reimbursement.

Conclusions
Modern interventional radiotherapy can be considered an important tool for the management of cancer patients to be integrated with other therapeutic strategies. The AIRO vision implies that specific strategic interventions must be other specialties in an interdisciplinary setting. We deeply believe that brachytherapy (interventional radiotherapy) is increasingly being considered and in the coming years, we expect more pronounced results.

 Disclosure
The authors report no conflict of interest.

References
1. Buyyounouski MK, Davis BJ, Prestidge BR et al. A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. Brachytherapy 2012; 11: 299-305.
2. Harkenrider MM, Block AM, Alektiar KM et al. American Brachytherapy Task Group Report: Adjunct vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy 2017; 16: 95-108.
3. Lancellotta V, Kovács G, Tagliaferri L et al. The role of personalized Interventional Radiotherapy (brachytherapy) in the management of older patients with non-melanoma skin cancer. J Geriatr Oncol 2019; 10: 514-517.
4. Lancellotta V, Kovács G, Tagliaferri L et al. Age is not a limiting factor in interventional radiotherapy (brachytherapy) for patients with localized cancer. Biomed Res Int 2018; 2018: 2178469.
5. Fricker J. Brachytherapy: halting the spiral of decline. CancerWorld Magazine 2019; 85: 4-15.
6. Autorino R, Vicenzi L, Tagliaferri L et al. A national survey of AIRO (Italian Association of Radiation Oncology) Brachytherapy (Interventional Radiotherapy) study group. J Contemp Brachytherapy 2018; 10: 254-259.
7. Tagliaferri L, Kovács G, Aristei C et al. Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey. J Contemp Brachytherapy 2019; 11: 48-53.
8. Han K, Milosevic M, Fyles A et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 2013; 87: 111-119.
9. Hoskin PJ, Rojas AM, Bownes PJ et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-222.
10. Gill BS, Lin JF, Kribak TC et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. Int J Radiat Oncol Biol Phys 2014; 90: 1083-1090.
11. Tagliaferri L, Pagliara MM, Fionda B et al. Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review. J Contemp Brachytherapy 2019; 11: 54-60.
12. Frakulli R, Galuppi A, Cannelli S et al. Brachytherapy in non melanoma skin cancer of eyelid: a systematic review. J Contemp Brachytherapy 2015; 7: 497-502.
13. Tagliaferri L, Manfrida S, Barbaro B et al. MITHRA – multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study. J Contemp Brachytherapy 2015; 7: 336-345.
14. Tagliaferri L, Lancellotta V, Fionda B et al. Subungual squamous cell carcinoma of the thumb treated by “function sparing approach” using contact radiotherapy (brachytherapy). Turk J Oncol 2019; 34: 283-286.
15. Colloca G, Di Capua B, Bellieni A et al. Musculoskeletal ageing, sarcopenia and cancer. J Geriatr Oncol 2019; 10: 504-509.
16. Guinot JL, Rembielak A, Perez-Calatayud J et al. GEC-ESTRO ACROP recommendations in skin brachytherapy. Radiother Oncol 2018; 126: 377-385.
17. Pieters BR, van der Steen-Banasik E, Smits GA et al. GEC-ESTRO/ACROP recommendations for performing bladder-sparing treatment with brachytherapy for muscle-invasive bladder carcinoma. Radiother Oncol 2017; 122: 340-346.
18. Kovács G, Martinez-Monge R, Budrukkar A et al. GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology. Radiother Oncol 2017; 122: 248-254.
19. Strnad V, Major T, Polgar C et al. ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost – GEC-ESTRO Breast Cancer Working Group practical recommendations. Radiother Oncol 2018; 128: 411-420.
20. Strnad V, Hannoun-Levi JM, Guinot JL et al. Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multichjatter interstitial brachytherapy after breast conserving closed cavity surgery. Radiother Oncol 2015; 115: 342-348.
21. Major T, Gutiérrez C, Guix B et al. Recommendations from GEC ESTRO Breast Cancer Working Group (II): Target definition and target delineation for accelerated or boost partial breast irradiation using multichatter interstitial brachytherapy after breast conserving open cavity surgery. Radiother Oncol 2016; 118: 199-204.
22. Hoskin PJ, Colombo A, Henry A et al. GEC/ESTRO recommendations on high dose rate brachytherapy for localised prostate cancer: an update. Radiother Oncol 2013; 107: 325-332.
23. Haie-Meder C, Pötter R, Van Limbergen E et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005; 74: 235-245.
24. Tagliaferri L, Fionda B, Bussu F et al. Interventional radiotherapy (brachytherapy) for squamous cell carcinoma of the nasal vestibule: a multidisciplinary systematic review. Eur J Dermatol 2019; 29: 417-421.
25. Pötter R, Haie-Meder C, Van Limbergen E et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment
planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. *Radiother Oncol* 2006; 78: 67-77.

26. Hepel JT, Arthur D, Shaitelman SF et al. American Brachytherapy Society consensus report for accelerated partial breast irradiation using interstitial multicatheter brachytherapy. *Brachytherapy* 2017; 16: 919-928.

27. Spratt DE, Soni PD, McLaughlin PW et al. American Brachytherapy Society Task Group Report: Combination of external beam therapy and brachytherapy for high-risk prostate cancer. *Brachytherapy* 2017; 16: 1-12.

28. Nag S, Erickson B, Thomadsen B et al. The role of palliative intervention in the setting of metastatic breast cancer. *Brachytherapy* 2017; 16: 919-928.

29. Bandera L, La Face B, Antonioli C et al. Survival and toxicity of radical radiotherapy (with or without brachytherapy) for FIGO stage I and II cervical cancer: a mono-institutional analysis. *Eur J Gynaecol Oncol* 2014; 35: 121-127.

30. Fellin G, Mirri MA, Santoro L et al. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions. *Br J Radiol* 2016; 89: 20150981.

31. Barbera F, Triggiani L, Buglione M et al. Salvage low dose rate brachytherapy for recurrent prostate cancer after external beam radiotherapy: results from a single institution with focus on toxicity and functional outcomes. *Clin Med Insights Oncol* 2017; 11: 1179554917738765.

32. Fozza A, Giannelli F, Blandino G et al. Mono-institutional Italian experience with a double-lumen balloon-brachytherapy device for early breast cancer: results at a 5-year minimum follow-up. *Tumori* 2014; 100: 163-168.

33. Guenzi M, Giannelli F, Azinwi C et al. Accelerated partial breast irradiation via the mammosite catheter: preliminary reports of a single-institution experience. *Breast* 2009; 15: 603-609.

34. Giannelli F, Chiola I, Belgioia I et al. Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy: a case report. *J Contemp Brachytherapy* 2017; 9: 572-578.

35. De Sanctis V, Agolli L, Valeriani M et al. External-beam radiotherapy and/or HDR brachytherapy in postoperative endometrial cancer patients: clinical outcomes and toxicity rates. *Radiol Med* 2013; 118: 311-322.

36. Autorino R, Mattiucci GC, Ardito F et al. Radiochemotherapy with gemcitabine in unresectable extrahepatic cholangiocarcinoma: long-term results of a phase ii study. *Anticancer Res* 2016; 36: 737-740.

37. Tagliaferri L, Bussu F, Fionda B et al. Perioperative HDR brachytherapy for reirradiation in head and neck recurrences: single-institution experience and systematic review. *Tumori* 2017; 103: 516-524.

38. Tagliaferri L, Bussu F, Rigante M et al. Endoscopy-guided brachytherapy for sinonasal and nasopharyngeal recurrences. *Brachytherapy* 2015; 14: 419-425.

39. Mangoni M, Gobitti C, Autorino R et al. External beam radiotherapy in thyroid carcinoma: clinical review and recommendations of the AIRO “Radiotherapia Metabolica” Group. *Tumori* 2017; 103: 114-123.

40. Colloca G, Corsonello A, Marzetti E et al. Treating cancer in older and oldest old patients. *Curr Pharm Des* 2015; 21: 1699-1705.

41. Lancellotta V, Cellini F, Fionda B et al. The role of palliative interventional radiotherapy (brachytherapy) in esophageal cancer: An AIRO (Italian Association of Radiotherapy and Clinical Oncology) systematic review focused on dysphagia-free survival. *Brachytherapy* 2019; pii: S1538-4721(19)30583-5.